SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

SANES

10.58

+3.52%↑

BBVA

19.475

+3.48%↑

BNP

89.45

+2.1%↑

CABK

11.255

+2.64%↑

INGA

25.99

+2.75%↑

Home・Akcijų sąrašas・Ipsen SA.

Ipsen SA.

Uždarymo kaina

SektoriusFinansų sektorius

158.9 1.47

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

156.2

Max

159.4

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-225M 110M
Pardavimai	36M 1.9B
P/E Sektoriaus vid.	29.171 58.236
Dividendų pajamingumas	0.84
Pelno marža	5.899
Darbuotojai	5,535
EBITDA	-171M 466M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-8.76% downside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.84% 4.64%
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.4B 13B
Ankstesnė atidarymo kaina	157.43
Ankstesnė uždarymo kaina	158.9

Naujienos nuotaikos

By Acuity

20%

80%

28 / 438 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

99.85 / 104 Palaikymas ir pasipriešinimas

Ipsen SA. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-19 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

2026-05-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

2026-05-19 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

F&P Healthcare's Outlook Key for Investors -- Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

2026-05-19 22:02; UTC

Uždarbis

ZTO Express (Cayman): Di Xu to Resign From Board

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q EPS 39c >ZTO

2026-05-19 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

2026-05-19 21:37; UTC

Uždarbis

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

2026-05-19 21:31; UTC

Įsigijimai, susijungimai, perėmimai

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

2026-05-19 21:01; UTC

Uždarbis

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

2026-05-19 20:58; UTC

Uždarbis

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

2026-05-19 20:46; UTC

Karštos akcijos

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

2026-05-19 20:43; UTC

Rinkos pokalbiai

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

2026-05-19 20:34; UTC

Uždarbis

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q EPS 5c >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q Sales $1.4B >JHX

2026-05-19 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5B

2026-05-19 20:18; UTC

Rinkos pokalbiai

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

2026-05-19 19:23; UTC

Rinkos pokalbiai

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ipsen SA. Prognozė

Kainos tikslas

By TipRanks

-8.76% į apačią

12 mėnesių prognozė

Vidutinis 143.8 EUR -8.76%

Aukščiausias 170 EUR

Žemiausias 117 EUR

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ipsen SA. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Ipsen SA. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

99.85 / 104Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

28 / 438 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.